.: DERLEME
Türk Toplumunda Yüksek Kardiyovasküler Riskli Hastalarda LDL-Kolesterol Düzeylerinin Değerlendirildiği Sistematik Derleme
A Systematic Evaluation of LDL-Cholesterol Levels of High Cardioovascular Risk Patients in Turkish Population
Turkiye Klinikleri J Cardiovasc Sci. 2019;31(3):162-93
doi: 10.5336/cardiosci.2019-70392
Makale Dili: TR
Tam Metin
ÖZET
Amaç: Türkiye'de yapılmış veya yayımlanmış makalelerin verilerini değerlendirerek Türk toplumunda kardiyovasküler riski yüksek olan hastalarda düşük dansiteli lipoprotein (LDL)-kolesterol düzeylerini ortaya koymaktır. Gereç ve Yöntemler: 1 Ocak 2008-31 Aralık 2017 tarihleri arasında yayımlanmış ve başlık veya özetinde LDL* ve TURK* terimlerini içeren yayınlar arasında, popülasyonunda kardiyovasküler hastalık (KVH), diabetes mellitus (DM) veya hipertansiyon olan ve bireylere ait ortalama LDL-kolesterol değeri içeren tam metin şeklindeki yayınlar çalışmaya dâhil edildi. Verilerin tanımlayıcı istatistiksel analizi yapıldı. Verilerin "hasta sayısına göre ağırlıklandırılmış ortalama değerleri" hesaplandı. Bulgular: Yüz elli yedi çalışmada yer alan toplam 35.855 hastanın ve 5.918 KVH olmayan bireyin verileri değerlendirildi KVH, DM ve hipertansiyon popülasyonlarında ortalama LDL-kolesterol düzeyleri sırasıyla 119,8±36,6 mg/dL, 124,2±36,4 mg/dL ve124,3±36,9 mg/dL'dir. KVH popülasyonunun %90,4'ünde, DM popülasyonunun %92,5'inde, hipertansiyon popülasyonunun %92,8'inde ve KVH olmayan bireylerin %91,4'ünde LDL-kolesterol 70 mg/dL'nin üzerindedir. Sonuç: KVH, DM ve hipertansiyonu olan toplam 35.855 hastanın büyük çoğunluğunda LDL-kolesterol ≤70 mg/dL hedeflenen düzeyinde değildir. Bu durum, prevalansı yüksek olan bu hastalıkların kontrolünü yetersiz kılarak ülkeye ciddi bir ekonomik yükü beraberinde getirmesi açısından önemlidir.
Anahtar Kelimeler: Diabetes mellitus; hipertansiyon; kardiyovaskuler hastalık; LDL-kolesterol; Türkiye
Amaç: Türkiye'de yapılmış veya yayımlanmış makalelerin verilerini değerlendirerek Türk toplumunda kardiyovasküler riski yüksek olan hastalarda düşük dansiteli lipoprotein (LDL)-kolesterol düzeylerini ortaya koymaktır. Gereç ve Yöntemler: 1 Ocak 2008-31 Aralık 2017 tarihleri arasında yayımlanmış ve başlık veya özetinde LDL* ve TURK* terimlerini içeren yayınlar arasında, popülasyonunda kardiyovasküler hastalık (KVH), diabetes mellitus (DM) veya hipertansiyon olan ve bireylere ait ortalama LDL-kolesterol değeri içeren tam metin şeklindeki yayınlar çalışmaya dâhil edildi. Verilerin tanımlayıcı istatistiksel analizi yapıldı. Verilerin "hasta sayısına göre ağırlıklandırılmış ortalama değerleri" hesaplandı. Bulgular: Yüz elli yedi çalışmada yer alan toplam 35.855 hastanın ve 5.918 KVH olmayan bireyin verileri değerlendirildi KVH, DM ve hipertansiyon popülasyonlarında ortalama LDL-kolesterol düzeyleri sırasıyla 119,8±36,6 mg/dL, 124,2±36,4 mg/dL ve124,3±36,9 mg/dL'dir. KVH popülasyonunun %90,4'ünde, DM popülasyonunun %92,5'inde, hipertansiyon popülasyonunun %92,8'inde ve KVH olmayan bireylerin %91,4'ünde LDL-kolesterol 70 mg/dL'nin üzerindedir. Sonuç: KVH, DM ve hipertansiyonu olan toplam 35.855 hastanın büyük çoğunluğunda LDL-kolesterol ≤70 mg/dL hedeflenen düzeyinde değildir. Bu durum, prevalansı yüksek olan bu hastalıkların kontrolünü yetersiz kılarak ülkeye ciddi bir ekonomik yükü beraberinde getirmesi açısından önemlidir.
Anahtar Kelimeler: Diabetes mellitus; hipertansiyon; kardiyovaskuler hastalık; LDL-kolesterol; Türkiye
ABSTRACT
Objective: To present the findings related with the low lipoprotein (LDL)- cholesterol levels of high cardiovascular risk patients in Turkish population by evaluating the data of articles performed and published in Turkey. Material and Methods: Among the articles including LDL* and TURK* in the title or abstract and published between 2008, January 1-2017, December 31, the full text articles on cardiovascular disease (CVD), diabetes mellitus (DM) or hypertension populations and with mean LDL cholesterol data of patients were included. The data were analyzed using the descriptive statistics. "The weighted mean of data considering patient numbers" were calculated. Results: The data of a total of 35.855 patients and 5.918 non-CVD subjects in 157 studies were evaluated. In CVD, DM and hypertension populations, the mean LDL-cholesterol levels were 119.8±36.6 mg/dL, 124.2±36.4 mg/dL, and 124.3±36.9 mg/dL, respectively. The LDL-cholesterol was higher than 70 mg/dL in 90.4% of CVD population, 92.5% of DM population, 92.8% of hypertension population and 91.4% of non-CVD subjects. Conclusion: In the majority of a total of 35.855 patients with CVD, DM and hypertension, the LDL-cholesterol was not in target levels of ≤70 mg/dL. This finding is important as it causes inadequate control of these diseases with high prevalence and is a high economic burden in the country.
Keywords: Diabetes mellitus; hypertension; cardiovascular disease; LDL-cholesterol; Turkey
Objective: To present the findings related with the low lipoprotein (LDL)- cholesterol levels of high cardiovascular risk patients in Turkish population by evaluating the data of articles performed and published in Turkey. Material and Methods: Among the articles including LDL* and TURK* in the title or abstract and published between 2008, January 1-2017, December 31, the full text articles on cardiovascular disease (CVD), diabetes mellitus (DM) or hypertension populations and with mean LDL cholesterol data of patients were included. The data were analyzed using the descriptive statistics. "The weighted mean of data considering patient numbers" were calculated. Results: The data of a total of 35.855 patients and 5.918 non-CVD subjects in 157 studies were evaluated. In CVD, DM and hypertension populations, the mean LDL-cholesterol levels were 119.8±36.6 mg/dL, 124.2±36.4 mg/dL, and 124.3±36.9 mg/dL, respectively. The LDL-cholesterol was higher than 70 mg/dL in 90.4% of CVD population, 92.5% of DM population, 92.8% of hypertension population and 91.4% of non-CVD subjects. Conclusion: In the majority of a total of 35.855 patients with CVD, DM and hypertension, the LDL-cholesterol was not in target levels of ≤70 mg/dL. This finding is important as it causes inadequate control of these diseases with high prevalence and is a high economic burden in the country.
Keywords: Diabetes mellitus; hypertension; cardiovascular disease; LDL-cholesterol; Turkey
REFERANSLAR:
- Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al; ESC Scientific Document Group. Authors/task force members: additional contributer. 2016 ESC/EAS guidelines for the management of dyslipidemias. Eur Heart J. 2017;37(39):2999-3058. [Crossref] [PubMed]
- Elisaf M, Pitsavos C, Liberopoulos E, Tziomalos K, Athyros VG. Updated Guidelines of the Hellenic Society of Atherosclerosis for the diagnosis and treatment of dyslipidemia-2014. Hellenic J Atheroscler. 2014;5(3):151-63.
- Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease-executive summary. Endocr Pract. 2017;23(4):479-97. [Crossref] [PubMed]
- Benjamin EJ, Balha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146-e603. [Crossref]
- Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis. 1998;141(Suppl 1):S57-S62. [Crossref]
- Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000. [Crossref] [PubMed] [PMC]
- Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 partipants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78. [Crossref]
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45. [Crossref] [PubMed]
- Sozmen K, Unal B, Sakarya S, Dinc G, Yardim N, Keskinkilic B, et al. Determinants of prevalence, awareness, treatment and control of LDL-C in Turkey. Anatol J Cardiol. 2016;16(6):370-84. [Crossref] [PMC]
- Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon Lipid Study. Endocrine. 2008;34(1-3):36-51. [Crossref] [PubMed]
- Unal B, Sozmen K, Ucku R, Ergor G, Soysal A, Baydur H, et al. High prevalence of cardiovascular risk factors in a Western urban Turkish population: a community-based study. Anadolu Kardiyol Derg. 2013;13(1):9-17. [Crossref]
- Oner S, Balcilar M, Erguder T. Turkiye Hanehalki Saglik Arastirmasi: Bulasici Olmayan Hastaliklarin Prevalansi 2017 (STEPS). Ankara: Dunya Saglik Orgutu Turkiye Ofisi; 2018. p.109.
- Zhang L, Qiao Q, Dong Y. Ethnic difference in lipid profiles. Dyslipidemia. In: Kelishadi R, ed. From Prevention to Treatment. 2012. Erisim tarihi: 31 Aralik 2018. Available from: http://www.intechopen.com/books/dyslipidemia-from-prevention-to-treatment/ethnic-differences-in-lipid-profiles. [Crossref]
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. [Crossref] [PubMed]
- Bays HE, Chapman RH, Fox KM, Grandy S; SHIELD Study Group. Comparison of self-reported survey (SHIELD) versus NHANES data estimating prevalence of dyslipidemia. Curr Med Res Opin. 2008;24(4):1179-86. [Crossref] [PubMed]
- Steinhagen-Thiessen E, Bramlage P, Losch C, Hauner H, Schunkert H, Vogt A, et al. Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol. 2008;7:31. [Crossref] [PubMed] [PMC]
- Simao AF, Precoma DB, Andrade JP, Correa Filho H, Saraiva JF, Oliveira GM; Brazilian Society of Cardiology. [I cardiovascular prevention guideline of the Brazilian Society of Cardiology - executive summary]. Arq Bras Cardiol. 2014;102(5):420-31.
- Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-39. [Crossref]
- Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol). National, regional, and global trends in serum total cholesterol since 1980: systemic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 miilion participants. Lancet. 2011;377(9765):578-86. [Crossref]
- Giampaoli S. CUORE: a sustainable cardiovascular disease prevention strategy. Eur J Cardiovasc Prev Rehabil. 2007;14(2):161-2. [Crossref] [PubMed]
- Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al; ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidemias: the Task Force for the management of dyslipidemias of the European SoGAety of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(Suppl 1):S1-S44.
- Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1- executive summary. J Clin Lipidol. 2014;8(5):473-88. [Crossref] [PubMed]
- Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel Members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. J Clin Lipidol. 2014;8(1):29-60.
- Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47. [Crossref] [PubMed]
- Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoproteins(a), apolipoproteins A-1 and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104(10):1108-13. [Crossref] [PubMed]
- Mahley RW, Palaoglu KE, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V, et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res. 1995;36(4):839-59.
- Onat A. Lipids, lipoproteins and apolipoproteins among turks, and impact on coronary heart disease. Anadolu Kardiyol Derg. 2004;4(3):236-45.
- Mahley RW, Mahley LL, Bersot TP, Pepin GM, Palaoglu KE. The Turkish lipid problem: low levels of high density lipoproteins. Turk J Endocr Metab. 2002;6(1):1-12.
- Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014;8(2):206-16. [Crossref] [PubMed]
- Kayikcioglu M, Tokgozoglu L, Kilickap M, Goksuluk H, Karaaslan D, Ozer N, et al. [Data on prevalence of dsylipidemia and lipid values in Turkey: systematic review and meta-analysis of epidemiological studies on cardiovascular risk factors]. Turk Kardiyol Dern Ars. 2018;46(7):556-74.
- Greenlund KJ, Zheng ZJ, Keenan NL, Giles WH, Casper ML, Mensah GA, et al. Trends in self-reported multiple cardiovascular disease risk factors among adults in the United States, 1991-1999. Arch Intern Med. 2004:164(2):181-8. [Crossref] [PubMed]
- Jaffer FA, O'Donnell CJ, Larson MG, Chan SK, Kissinger KV, Kupka MJ, et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Biol. 2002;22(5):849-54. [Crossref] [PubMed]
- Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet. 2001;357(9256):577-81. [Crossref]
- Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106(16):2055-60. [Crossref] [PubMed]
- Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485-94.
- Viviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIME 22 substudy. J Am Coll Cardiol. 2005;46(8):1411-6. [Crossref] [PubMed]
- Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. Lipids Health Dis. 2014;13:183. [Crossref] [PubMed] [PMC]
- Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, et al. High-dose atorvastation after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-59. [Crossref] [PubMed]
- Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation. 1992;86(3):1046-60. [Crossref] [PubMed]
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastation in 20,536 high-risk individulas: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22. [Crossref]
- Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastation on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:(14)1001-9. [Crossref] [PubMed]
- Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-22. [Crossref] [PubMed]
- Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. [Crossref] [PubMed]
.: İşlem Listesi